Compassionate Use of the Incraft AAA Stent Graft System
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To treat patients with abdominal aortic aneurysms requiring endovascular repair outside of the clinical protocol through compassionate use.
| Condition | Intervention |
|---|---|
|
Abdominal Aortic Aneurysm |
Device: Endovascular AAA repair |
| Study Type: | Expanded Access What is Expanded Access? |
| Official Title: | Compassionate Use of the Incraft AAA Stent Graft System |
| Study Start Date: | November 2012 |
| Estimated Study Completion Date: | May 2018 |
| Estimated Primary Completion Date: | May 2014 (Final data collection date for primary outcome measure) |
In the US, abdominal aortic aneurysms (AAA) are found in 4-8% of older men and 0.5-1.5% of older women, resulting in 30,000-40,000 elective procedures and 1,400 peri-operative deaths. The most significant complication of AAA is an aneurysm sac rupture from which more than 15,000 patients die annually and is the 15th leading cause of death in elderly between 60 to 85 years of age . In Japan, it is estimated that approximately 14,000 endovascular aneurysm repair (EVAR) and open surgical repair cases were performed in the year 2010 .
Abdominal aortic aneurysms can be treated three ways: (1) Medical management; (2) Open surgical repair; and (3) Endovascular aneurysm repair (EVAR). EVAR has emerged as an alternative treatment of AAA for most patients. It is less invasive than open repair and carries lower rates of early mortality and morbidity . It has also extended treatment options to patients who cannot undergo conventional surgical procedures due to a high operative risk. As EVAR technology evolves, it allows treatment of AAA with increasing complexity of the aortic neck and access vessels.
The InCraft™ AAA Stent Graft System is designed for endovascular repair of infrarenal AAAs with complex aortic anatomies. This stent-graft system utilizes nitinol stent and polyester graft technology in an ultra-low profile delivery system, which assists the physician in deploying the device in a controlled, consistent, and precise manner within the aortic neck and iliac arteries. By isolating the aneurysmal sac, the system provides an alternative blood flow path to relieve pressure on the arterial vessel walls and minimize aneurysm growth and the potential for aneurysm sac rupture.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
- Obtain an independent assessment by an uninvolved physician.
- Obtain informed consent from the patient or legal representative. The consent form used should provide information pertinent to the patient's specific situation. (If appropriate, the study consent form may be used with an addendum to inform the patient of concerns specific to their situation.)
- Obtain clearance from the institution in accordance with their policies.
- Notify the institutional review board and comply with their procedures.
Contacts and Locations| Contact: Amy Orlick | 908-541-4347 | aorlick@its.jnj.com |
| United States, New Jersey | |
| Cordis Corporation | |
| Bridgewater, New Jersey, United States, 08807 | |
| Contact: Amy Orlick 908-541-4347 aorlick@its.jnj.com | |
| Principal Investigator: | Michel S Makaroun, MD | University of Pittsburgh |
| Principal Investigator: | Takao Ohki, MD | Jikei University School of Medicine |
More Information
No publications provided
| Responsible Party: | Cordis Corporation |
| ClinicalTrials.gov Identifier: | NCT01776450 History of Changes |
| Other Study ID Numbers: | G120003/S4 |
| Study First Received: | January 21, 2013 |
| Last Updated: | January 23, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Cordis Corporation:
|
Abdominal Aortic Aneurysm |
Additional relevant MeSH terms:
|
Aneurysm Aortic Aneurysm Aortic Aneurysm, Abdominal |
Vascular Diseases Cardiovascular Diseases Aortic Diseases |
ClinicalTrials.gov processed this record on May 16, 2013